Atara Biotherapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Atara Biotherapeutics, Inc. (ATRA) on May 8, 2020. The report discloses a corporate governance event regarding the appointment of a new member to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change disclosed is the appointment of Dr. Maria Grazia Roncarolo to the Board of Directors. The appointment was made on May 8, 2020, with an effective date of May 11, 2020. Dr. Roncarolo was selected to fill a vacant seat and will serve an initial term expiring at the 2023 annual meeting of stockholders. The Board determined she is independent under applicable guidelines and listing standards.
Compensation and Governance Details
- Role: Independent Director (no committee assignments at the time of filing).
- Annual Retainer: $45,000, starting on the effective date, pro-rated for partial periods.
- Equity Grant: Option to purchase 59,500 shares of Common Stock.
- Vesting Schedule: 1/3 of the option vests on the first, second, and third anniversaries of the grant date, subject to continuous service.
- Other: A standard indemnification agreement was executed.
Investor Verification Checklist
- Verify Dr. Roncarolo's professional background and independence status in the company's Proxy Statement.
- Review the full "Non-Employee Director Compensation" section in the 2020 Proxy Statement for details on the compensation plan.
- Confirm the current status of the Board seat vacancy and any subsequent committee assignments for Dr. Roncarolo.
- Check for any related party transactions or conflicts of interest not disclosed in this specific 8-K.